ArticleBreast cancer research : BCR2000
P53 autoantibodies in 1006 patients followed up for breast cancer.
Article in Breast cancer research : BCR, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Clinical utility of anti-p53 auto-antibody: systematic review and focus on colorectal cancer.World journal of gastroenterology · 2013Pooled it
- Autoantibodies as biomarkers for breast cancer diagnosis and prognosis.Frontiers in immunology · 2022Review
- Autoantibodies in Early Detection of Breast Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Article
- Longitudinal serum autoantibody repertoire profiling identifies surgery-associated biomarkers in lung adenocarcinoma.EBioMedicine · 2020Article
- Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Early Diagnosis of Breast Cancer.Sensors (Basel, Switzerland) · 2017Review
- Cancer prognostics by direct detection of p53-antibodies on gold surfaces by impedance measurements.Small (Weinheim an der Bergstrasse, Germany) · 2012Article
- Association between AgNORs and Immunohistochemical Expression of ER, PR, HER2/neu, and p53 in Breast Carcinoma.Pathology research international · 2011Article
- Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer.Journal of proteome research · 2008Article
- Lymph node status as a guide to selection of available prognostic markers in breast cancer: the clinical practice of the future?Diagnostic pathology · 2006Article
- Naturally occurring B-cell responses to breast cancer.Cancer immunology, immunotherapy : CII · 2003Review
- Autoimmunity to the M(r) 32,000 subunit of replication protein A in breast cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2002Article
- The p53 pathway in breast cancer.Breast cancer research : BCR · 2002Review
- Heterologous prime/boost immunization with p53-based vaccines combined with toll-like receptor stimulation enhances tumor regression.Journal of immunotherapy (Hagerstown, Md. : 1997)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serial plasma samples from 1006 patients with breast cancer revealed: (i) no correlation of p53 autoantibody status with disease status at the time of sample collection, or with menopausal status at time of primary diagnosis of breast cancer; (ii) 155 out of 1006 (15%) of patients were positive for p53 autoantibodies, and these patients tended to have a persistent autoantibody status throughout follow up, irrespective of disease behaviour; and (iii) where a negative autoantibody status was found at primary diagnosis of breast cancer, this negative status persisted throughout follow up, irrespective of later disease behaviour. We conclude that screening for p53 autoantibody status is not informative on residual tumour activity nor on therapeutic responsiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.